Pre-leukaemic' mutations are thought to promote clonal expansion of haematopoietic stem cells (HSCs) by increasing self-renewal and competitiveness 1 ; however, mutations that increase HSC proliferation tend to reduce competitiveness and self-renewal potential, raising the question of how a mutant HSC can sustainably outcompete wild-type HSCs. Activating mutations in NRAS are prevalent in human myeloproliferative neoplasms and leukaemia 2 . Here we show that a single allele of oncogenic Nras G12D increases HSC proliferation but also increases reconstituting and self-renewal potential upon serial transplantation in irradiated mice, all prior to leukaemia initiation. Nras G12D also confers long-term self-renewal potential to multipotent progenitors. To explore the mechanism by which Nras G12D promotes HSC proliferation and self-renewal, we assessed cell-cycle kinetics using H2B-GFP label retention and 5-bromodeoxyuridine (BrdU) incorporation. Nras G12D had a bimodal effect on HSCs, increasing the frequency with which some HSCs divide and reducing the frequency with which others divide. This mirrored bimodal effects on reconstituting potential, as rarely dividing Nras G12D HSCs outcompeted wild-type HSCs, whereas frequently dividing Nras G12D HSCs did not. Nras G12D caused these effects by promoting STAT5 signalling, inducing different transcriptional responses in different subsets of HSCs. One signal can therefore increase HSC proliferation, competitiveness and self-renewal through bimodal effects on HSC gene expression, cycling and reconstituting potential.
'Pre-leukaemic' mutations are thought to promote clonal expansion of haematopoietic stem cells (HSCs) by increasing self-renewal and competitiveness 1 ; however, mutations that increase HSC proliferation tend to reduce competitiveness and self-renewal potential, raising the question of how a mutant HSC can sustainably outcompete wild-type HSCs. Activating mutations in NRAS are prevalent in human myeloproliferative neoplasms and leukaemia 2 . Here we show that a single allele of oncogenic Nras G12D increases HSC proliferation but also increases reconstituting and self-renewal potential upon serial transplantation in irradiated mice, all prior to leukaemia initiation. Nras G12D also confers long-term self-renewal potential to multipotent progenitors. To explore the mechanism by which Nras G12D promotes HSC proliferation and self-renewal, we assessed cell-cycle kinetics using H2B-GFP label retention and 5-bromodeoxyuridine (BrdU) incorporation. Nras G12D had a bimodal effect on HSCs, increasing the frequency with which some HSCs divide and reducing the frequency with which others divide. This mirrored bimodal effects on reconstituting potential, as rarely dividing Nras G12D HSCs outcompeted wild-type HSCs, whereas frequently dividing Nras G12D HSCs did not. Nras G12D caused these effects by promoting STAT5 signalling, inducing different transcriptional responses in different subsets of HSCs. One signal can therefore increase HSC proliferation, competitiveness and self-renewal through bimodal effects on HSC gene expression, cycling and reconstituting potential.
To gain a durable competitive advantage, mutant HSCs must sustainably self-renew more frequently than wild-type HSCs. Yet increased HSC division is almost always associated with reduced self-renewal potential and HSC depletion [3] [4] [5] . Many oncogenic mutations increase HSC proliferation but deplete HSCs, preventing clonal expansion 6 . Some oncogenic mutations do increase HSC self-renewal, including overexpression of Ezh2 (ref. 7) or Csf3r truncation 8 , and deletion of p18 INK4C (ref. 9 ), Tet2 (ref. 10) , Dnmt3a 11 or Lnk 12, 13 . However, it remains uncertain whether these mutations can account for pre-leukaemic expansion.
Human leukaemias commonly have mutations that increase Ras signalling, including NRAS or KRAS point mutations 2 . Mouse models with conditional expression of oncogenic Kras G12D develop a rapid onset, aggressive myeloproliferative neoplasm (MPN) 14, 15 . Kras G12D drives HSCs into cycle and reduces HSC frequency 14, 15 . Nras G12D knock-in mice, on the other hand, develop an indolent MPN with delayed onset and prolonged survival 16, 17 . NF1 inactivation 18 or Nras G12D expression 17, 19 allow bone marrow cells to outcompete wild-type cells in transplantation assays, but it remains unclear whether they promote sustained pre-leukaemic expansion, or how that might occur.
To conditionally activate a single allele of Nras G12D in HSCs we generated Mx1-cre; Nras G12D/1 mice in which the oncogenic G12D mutation was knocked into the endogenous Nras locus along with a floxed stop cassette 20 . To induce Nras G12D expression, mice were administered poly-inosine:poly-cytosine (pIpC) at 6-10 weeks after birth (Extended Data Fig. 1 ). At 2 weeks and 3 months after pIpC treatment, more than twice as many Nras G12D/1 CD150 1 CD48 2 Lineage 2 Sca-1 1 c-kit 1 (CD150 1 CD48 2 LSK) HSCs 21 incorporated a 24-h pulse of BrdU as compared to control HSCs (P , 0.01; Fig. 1a ). Consistent with this, twice as many Nras G12D/1 HSCs were in G1 phase of the cell cycle as compared to control HSCs (Extended Data Fig. 1b ). This increase in HSC proliferation did not significantly affect the number of HSCs or multipotent progenitors (MPPs) 2 weeks after Nras G12D activation ( Fig. 1c ). However, Mx1-cre; Nras G12D/1 mice had significantly more LSK cells in the bone marrow and spleen ( Fig. 1c ). We also observed a twofold increase in BrdU incorporation in HSCs, as well as an expansion of LSK cells in Vav1-cre; Nras G12D/1 mice as compared to controls ( Fig. 1b ; Extended Data Fig. 2a ). Thus Nras G12D increased HSC division and expanded the pool of primitive haematopoietic progenitors.
To test competitiveness we transplanted 5 3 10 5 whole bone marrow cells from Mx1-cre; Nras G12D/1 or control donors into irradiated wild-type recipients along with 5 3 10 5 recipient bone marrow cells. The Nras G12D/1 cells gave significantly higher levels of reconstitution than control cells in all lineages for at least 20 weeks after transplantation ( Fig. 1d ). In recipients of control donor cells, 69 6 13% of HSCs, 47 6 12% of MPPs and 44 6 12% of LSK cells were donor-derived ( Fig. 1e ); however, in recipients of Nras G12D/1 donor cells, 93 6 8% of HSCs, 90 6 8% of MPPs, and 85 6 15% of LSK cells were donor-derived ( Fig. 1e ). Nras G12D/1 HSCs therefore outcompeted wild-type HSCs.
To further test whether Nras G12D/1 HSCs could outcompete wildtype HSCs we transplanted 10 CD150 1 CD48 2 LSK donor HSCs from the bone marrow of Mx1-cre; Nras G12D/1 or littermate control mice (2 weeks after finishing pIpC) into irradiated wild-type recipients along with 3 3 10 5 recipient bone marrow cells. The Nras G12D/1 HSCs gave significantly higher levels of reconstitution compared to control donor HSCs in all lineages for at least 20 weeks after transplantation ( Fig. 1f ).
To assess self-renewal potential we serially transplanted 3 3 10 6 whole bone marrow cells from three or four recipients per treatment into 2 to 5 irradiated mice per recipient (depending on the number of bone marrow cells we recovered) during each round of transplantation. In secondary, tertiary and quaternary recipient mice we continued to observe significantly higher levels of reconstitution from the Nras G12D/1 donor cells than from control donor cells in all lineages ( Fig. 2a-c) . In tertiary recipient mice, the control cells gave only transient multilineage reconstitution as they appeared to exhaust their self-renewal potential. In contrast, the Nras G12D/1 HSCs gave high levels of long-term multilineage reconstitution in all 9 tertiary recipients, suggesting increased self-renewal potential. In quaternary recipient mice, Nras G12D/1 donor cells continued to give long-term multilineage reconstitution in most recipients whereas control donor cells gave only low levels of transient lymphoid reconstitution (Fig. 2c ). Nras G12D thus increased the selfrenewal potential of HSCs in addition to increasing their rate of division ( Fig. 1a ) and their ability to compete with wild-type HSCs (Fig. 1d, f) .
A fifth round of transplantation from four quaternary recipients of Nras G12D/1 cells did not yield any multilineage reconstitution by donor cells in the recipient mice (Extended Data Fig. 3 ). Nras G12D/1 HSCs therefore eventually exhausted their self-renewal potential despite selfrenewing more than control cells. Serial transplantation of Vav1-cre; Nras G12D/1 whole bone marrow cells showed that Nras G12D/1 significantly increased HSC competitiveness in this genetic background as well (Extended Data Fig. 2b, c) .
To test whether Nras G12D expression influenced the reconstituting potential of MPPs, we transplanted 10 donor CD150 2 CD48 2 LSK cells 22 from the bone marrow of Mx1-cre; Nras G12D/1 or littermate control mice (2 weeks after finishing pIpC) into irradiated recipients along with 3 3 10 5 recipient bone marrow cells. Only one of 14 recipients of control MPPs exhibited long-term multilineage reconstitution by donor cells (Extended Data Fig. 4a ). In contrast, 8 of 17 recipients of Nras G12D/1 MPPs were long-term multilineage reconstituted by donor cells. Nras G12D/1 MPPs were thus significantly (P , 0.01 across three independent experiments) more likely to give long-term multilineage reconstitution than control MPPs.
Nras G12D did not detectably affect the reconstituting potential of 25 CD150 1 CD48 1 LSK cells or 100 CD150 2 CD48 1 LSK cells (which contain restricted myeloid progenitors 22 ) upon transplantation into irradiated mice (Extended Data Fig. 4b , c). Nras G12D/1 thus increases the self-renewal potentials of HSCs and MPPs but not necessarily other progenitors.
We did not detect any evidence of leukaemia or MPN in any of the recipient mice from the first, second, third or fourth rounds of serial transplantation in terms of blood cell counts (Extended Data Fig. 5 ) or histology (data not shown). Only two recipients of Nras G12D/1 cells and two recipients of control cells died spontaneously in these experiments. The effects of Nras G12D/1 on HSC function therefore occurred in the absence of leukaemogenesis.
To assess the effect of Nras G12D/1 on HSC cycling over time we mated the Mx1-cre; Nras G12D/1 mice with Col1A1-H2B-GFP; Rosa26-M2-rtTA double transgenic mice 4 . These mice allowed us to label HSCs with H2B-GFP during a 6-week period of doxycycline administration and then to follow the division history of all cells in the HSC pool as they diluted H2B-GFP with each round of division during a subsequent 12-15-week chase without doxycycline.
Two weeks after pIpC treatment, Mx1-cre; Nras G12D/1 ; Col1A1-H2B-GFP; Rosa26-M2-rtTA mice and Nras G12D/1 ; Col1A1-H2B-GFP; Rosa26-M2-rtTA controls (lacking cre) exhibited similar background levels of GFP fluorescence (Fig. 3a) . After treating the mice with doxycycline for 6 weeks, all HSCs were strongly GFP 1 (Fig. 3a ). Mx1-cre; Nras G12D/1 and control HSCs exhibited indistinguishable levels of H2B-GFP labelling Nras G12D/1 (G12D/1) and littermate control (Ctrl) mice at 2 weeks and 3 months after pIpC treatment (n 5 3 mice per treatment). b, BrdU incorporation by CD150 1 CD48 2 LSK HSCs from Vav1-cre; Nras G12D/1 mice (G12D/1) or littermate controls at 6-10-weeks of age (n 5 3). c, The total number of CD150 1 CD48 2 LSK HSCs, CD150 2 CD48 2 LSK MPPs, and LSK cells in the bone marrow and spleens of Mx1-cre; Nras G12D/1 (G12D/1) and littermate control mice at 2 weeks after pIpC treatment (n 5 5 mice per treatment). d, Donor bone marrow cells (5 3 10 5 ) from Mx1-cre; Nras G12D/1 (G12D/1) or littermate control mice at 2 weeks after pIpC treatment (n 5 3 donors per genotype) were transplanted into irradiated recipient mice (n 5 15 recipients per genotype) along with 5 3 10 5 recipient bone marrow cells. Donor cell reconstitution in the myeloid (Mac-1 1 cells), B (B220 1 ), and T (CD3 1 ) cell lineages for 4 to 20 weeks after transplantation. e, Recipients of Mx1-cre; Nras G12D/1 (G12D/1) bone marrow cells (n 5 5) had significantly (P , 0.05) higher proportions of donor-derived HSCs, MPPs and LSK cells compared to recipients of control bone marrow cells. f, Ten donor HSCs from Mx1-cre; Nras G12D/1 (G12D/1) or littermate control mice at 2 weeks after pIpC treatment (n 5 3 donors per genotype) were transplanted into irradiated recipient mice (n 5 14 recipients per genotype) along with 3 3 10 5 recipient bone marrow cells. Data represent mean 6 s.d. Two-tailed Student's t-tests were used to assess statistical significance. *P , 0.05, **P , 0.01, ***P , 0.001. 
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immediately after doxycycline treatment ( Fig. 3a) . After a 12-week chase without doxycycline, the Nras G12D and control HSCs exhibited a wide range of GFP expression levels (Fig. 3b ). In contrast, most bone marrow cells from Mx1-cre; Nras G12D/1 and control mice exhibited GFP levels similar to background (Extended Data Fig. 6a ). To assess the frequencies of HSCs that were most infrequently cycling, most frequently cycling, and moderately cycling we determined the frequencies of H2B-GFP hi HSCs (with GFP levels similar to freshly labelled cells, see Fig. 3a ), H2B-GFP 2 HSCs (with little or no GFP expression above background, see Fig. 3a ), and H2B-GFP lo HSCs (with intermediate levels of GFP), respectively. In 8 independent experiments, Nras G12D significantly (P , 0.05 by two-way ANOVA) increased the frequencies of both the H2B-GFP 2 frequently cycling HSCs and the H2B-GFP hi infrequently cycling HSCs in every pair of mice we examined (n 5 8) ( Fig. 3b ). There was a corresponding significant decrease in the frequency of H2B-GFP lo HSCs in Nras G12D mice.
The median level of GFP fluorescence in H2B-GFP 2 HSCs was significantly lower in Nras G12D/1 as compared to control mice (Extended Data Fig. 6b ), suggesting that H2B-GFP 2 Nras G12D/1 HSCs underwent more rounds of division on average. In contrast, the median level of GFP fluorescence in H2B-GFP hi HSCs was significantly higher in Nras G12D/1 as compared to control mice (Extended Data Fig. 6b ), suggesting that H2B-GFP hi Nras G12D/1 HSCs tended to divide less than control H2B-GFP hi HSCs on average. Nras G12D/1 thus had a bimodal effect, increasing the division of some HSCs and reducing the division of other HSCs.
We followed another cohort of age and sex-matched pairs of Mx1cre; Nras G12D/1 and control mice for 15 weeks after doxycycline removal. In five independent experiments, Nras G12D significantly increased the frequency of H2B-GFP hi HSCs in every pair of mice we examined (n 5 7; P , 0.05) ( Fig. 3c ). We observed increased frequencies of H2B-GFP 2 HSCs in the Nras G12D/1 mice from some pairs but not others, and overall the effect was not statistically significant ( Fig. 3c ). As the rapidly dividing subset of Nras G12D/1 HSCs differentiates more quickly than control HSCs (Fig. 3d ), prolonged periods of chase after H2B-GFP labelling may not be appropriate to quantify the frequency of these cells. Nras G12D/1 significantly increased the rate at which MPPs divided (Extended Data Fig. 6c ).
To test the relationship between division history and competitiveness we transplanted 15 CD150 1 CD48 2 LSK H2B-GFP hi HSCs, 50 H2B-GFP lo moderately cycling HSCs, or 75 H2B-GFP 2 frequently cycling HSCs from Nras G12D/1 or control donor mice after 12 weeks of chase into irradiated wild-type recipients along with 3 3 10 5 recipient bone marrow cells. The Nras G12D/1 H2B-GFP 2 frequently cycling HSCs gave significantly lower levels of donor cell reconstitution, at least in the myeloid lineages, as compared to control H2B-GFP 2 HSCs (Fig. 3d ). In contrast, the Nras G12D/1 H2B-GFP lo and H2B-GFP hi HSCs gave significantly (P , 0.05) higher levels of donor cell reconstitution in all lineages than the control H2B-GFP lo and H2B-GFP hi HSCs (Fig. 3d ). Nras G12D/1 thus reduced the division and increased the competitiveness of some HSCs while increasing the division and reducing the competitiveness of other HSCs.
We continuously administered BrdU to Mx1-cre; Nras G12D/1 versus control mice beginning 2 weeks after pIpC treatment. We assessed the frequency of BrdU 1 HSCs after 4, 10, 20 and 30 days of BrdU treatment (Extended Data Fig. 6d ). Relative to control HSCs, significantly more Mx1-cre; Nras G12D/1 HSCs incorporated BrdU after 4 days (32 6 0.1% versus 24 6 1.2%, P , 0.01) and 10 days (64 6 5.9% versus 45 6 3.6%, P , 0.02) of BrdU administration. In contrast, significantly fewer Mx1-cre; Nras G12D/1 HSCs incorporated BrdU after 20 days (78 6 4.7% versus 86 6 0.7%, P , 0.05) and 30 days (86 6 3.4% versus 92 6 4.8%, P , 0.02) of BrdU administration. These data are consistent with the H2B-GFP label retention data in demonstrating that some Nras G12D/1 HSCs divide more frequently while other Nras G12D/1 HSCs divide less frequently than control HSCs.
We detected the activation of the canonical Ras effector, ERK, in bone marrow cells from Mx1-cre; Nras G12D/1 and Mx1-cre; Nras G12D/G12D mice but not in LSK stem/progenitor cells or Lineage 2 c-kit 1 Sca-1 2 myeloid progenitors (Extended Data Fig. 8a ). We treated Mx1-cre; Nras G12D/1 or control mice with the MEK inhibitors, PD0325901 (5 mg per kg per day) or AZD6244 (25 mg per kg per day), and assessed the effects on BrdU incorporation in CD150 1 CD48 2 LSK HSCs. After eight days of treatment, splenocytes from PD0325901-treated mice of both genotypes showed reduced pERK levels (Extended Data Fig. 8b ), but this did not affect the increased rate of BrdU incorporation by Nras G12D/1 HSCs (Extended Data Fig. 8c ). In contrast, when we performed the same experiments with AZD6244, pERK activation was completely blocked in bone marrow and spleen (Extended Data Fig. 8d ) and the increased cycling of Nras G12D/1 HSCs was abolished (Extended Data Fig. 8e ). These data suggest that the more stringent inhibition of pERK activation by AZD6244 blocks the effect of Nras G12D/1 on HSC cycling. 
Time after transplant (weeks) Despite overlapping standard deviations, differences were statistically significant in pairwise t-tests because the frequencies of H2B-GFP 2 HSCs and H2B-GFP hi HSCs were always higher in the Nras G12D/1 mice. c, GFP expression in HSCs from pairs of age and sex-matched Nras G12D/1 and control mice after 15 weeks of chase without doxycycline (n 5 7 mice from 5 independent experiments). Nras G12D/1 mice always had higher frequencies of H2B-GFP hi HSCs (P , 0.05 by pairwise t-tests). d, Transplantion of 15 CD150 1 CD48 2 LSK H2B-GFP hi HSCs, 50 H2B-GFP lo HSCs or 75 H2B-GFP 2 HSCs from Nras G12D/1 or littermate control mice after 12 weeks of chase into irradiated wild-type recipients along with 3 3 10 5 recipient bone marrow cells (2 independent experiments with a total of 7 recipients per genotype). Data represent mean 6 s.d. Unless otherwise stated, two-tailed student's t-tests were used to assess statistical significance. *P , 0.05, **P , 0.01, ***P , 0.001.
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We did not detect increased Akt (Extended Data Fig. 8f ), S6, or p38 ( Fig. 4a ) phosphorylation in whole bone marrow cells, CD48 2 LSK cells (HSCs and MPPs) or CD48 1 LSK cells (mainly restricted progenitors 22 ) from Mx1-cre; Nras G12D/1 mice.
We performed gene expression profiling of H2B-GFP 2 and H2B-GFP hi CD150 1 CD48 2 LSK HSCs from 3 pairs of Mx1-cre; Nras G12D/1 ; Col1A1-H2B-GFP; Rosa26-M2-rtTA mice and littermate controls 12 weeks after removal of doxycycline. Gene set enrichment analysis (GSEA) revealed that cell-cycle genes were significantly enriched in H2B-GFP 2 Nras G12D/1 HSCs as compared to H2B-GFP 2 control HSCs (P , 0.0001), but not in H2B-GFP hi Nras G12D/1 HSCs as compared to H2B-GFP hi control HSCs (Extended Data Fig. 7d ). DNA replication genes and RNA polymerase genes were significantly enriched in H2B-GFP 2 Nras G12D/1 HSCs as compared to H2B-GFP 2 control HSCs (P , 0.05) but were significantly depleted in H2B-GFP hi Nras G12D/1 HSCs as compared to H2B-GFP hi control HSCs (P , 0.01; Extended Data Fig. 7e, f) . These data demonstrate different transcriptional responses to Nras activation in H2B-GFP 2 as compared to H2B-GFP hi HSCs: genes associated with cell cycling were induced by Nras activation in the H2B-GFP 2 HSCs but repressed by Nras activation in the H2B-GFP hi HSCs.
Only two genes showed a similar change in expression with Nras activation in all of the multipotent cells we studied (P # 0.05 and fold change $ 2; Extended Data Fig. 7a-c) . One of these, suppressor of cytokine signalling 2 (Socs2), was significantly reduced in expression in Nras G12D/1 as compared to control cells by microarray and quantitative PCR with reverse transcription (qRT-PCR) (Extended Data Figs 7c and 8g-i). SOCS2 negatively regulates STAT signalling in haematopoietic cells 23, 24 . We observed an increase in phosphorylated STAT5, but not STAT3, levels in Nras G12D/1 as compared to control CD48 2 LSK cells, without affecting total STAT5 levels (Fig. 4a, b and Extended Data Fig. 8j ).
To test whether the increased STAT5 phosphorylation in Nras G12D/1 CD48 2 LSK cells increased HSC proliferation and self-renewal, we mated Stat5ab fl/1 mice 25 with Mx1-cre; Nras G12D/1 mice. Two weeks after finishing pIpC treatment, the western blot of flow cytometrically sorted CD48 2 LSK cells confirmed that deletion of one allele of Stat5ab in Nras G12D/1 HSCs reduced the levels of pSTAT5 and total STAT5 (Extended Data Fig. 8k ). Stat5ab 2/1 HSCs showed normal BrdU incorporation and Nras G12D/1 HSCs showed increased proliferation relative to control HSCs (Fig. 4c ). Deletion of one allele of Stat5ab in Nras G12D/1 HSCs significantly reduced the rate of BrdU incorporation (P , 0.05). A reduction in STAT5 levels thus rescued the effects of Nras G12D on HSC cycling. Neither deletion of Stat5ab nor activation of Nras G12D/1 significantly affected BrdU incorporation by the myeloid progenitors we examined (Extended Data Fig. 8l ).
We next transplanted 5 3 10 5 whole bone marrow cells from control, Mx1-cre; Nras G12D/1 , Mx1-cre; Stat5ab 2/1 , or Mx1-cre; Nras G12D/1 ; Stat5ab -/1 (double mutant) donors (2 weeks after finishing pIpC treatment) into irradiated wild-type recipients along with 5 3 10 5 recipient bone marrow cells. Nras G12D/1 cells gave significantly higher levels of reconstitution than control cells in all lineages for at least 20 weeks after transplantation (Fig. 4d ). Loss of one Stat5ab allele, reduced the level of reconstitution by donor cells relative to control cells but the difference was not statistically significant. In contrast, loss of a single allele of Stat5ab in the Nras G12D/1 background completely blocked the increased reconstitution by Nras G12D/1 cells such that levels of donor cell reconstitution were indistinguishable from control cells (Fig. 4d ). An increase in STAT5 signalling is therefore required for increased competitiveness by Nras G12D HSCs.
Nras G12D is probably an early mutation in some leukaemias as it is widely observed in both MPN and myeloid leukaemias 2 , and Nras G12D mutations in mice lead only to a late onset MPN with prolonged survival 16, 17 . NRAS and KRAS mutations are frequently among the first mutations observed in pre-leukaemic clones that precede chronic myelomonocytic leukaemia (CMML) 26 . Some juvenile myelomonocytic leukaemia (JMML) patients undergo remission, with or without therapy, yet continue to carry NRAS mutations in their haematopoietic cells 27, 28 . Germline NRAS mutations have also been reported in JMML patients 29 , or patients with Noonan syndrome that develop JMML 30 . The evidence that NRAS mutations can be found in normal haematopoietic cells, despite predisposing for the development of neoplasms, is consistent with our conclusion that they promote pre-leukaemic clonal expansion.
Our data provide a molecular explanation for how pre-leukaemic clonal expansion may occur. Nras G12D/1 has a bimodal effect on HSCs, increasing self-renewal potential and reducing division in one subset of HSCs while increasing division and reducing self-renewal in another subset of HSCs. Short-lived but rapidly dividing Nras G12D/1 HSCs presumably outcompete wild-type HSCs and are replenished over time by quiescent Nras G12D/1 HSCs that are slowly recruited into cycle. It will be interesting to determine whether the ability to induce bimodal responses in stem cell pools is a common feature of mutations that promote pre-malignant clonal expansion.
METHODS SUMMARY
Mice. All mice were housed in the Unit for Laboratory Animal Medicine at the University of Michigan and protocols were approved by the University of Michigan Committee on the Use and Care of Animals. Fig. 8j . Cells were stimulated in culture with stem cell factor and thrombopoietin for 30 min before protein extraction. c, The frequency of BrdU 1 CD150 1 CD48 2 LSK HSCs after a 24-h pulse of BrdU to Mx1-cre; Stat5ab fl/1 (Stat5ab 2/1 ) mice, Mx1-cre; Nras G12D/1 (G12D/1) mice, Mx1-cre; Nras G12D/1 ; Stat5ab fl/1 (G12D/1; Stat5ab 2/1 ) compound mutant mice, or control mice (n 5 4). d, Donor bone marrow cells (5 3 10 5 ) from mice of each genotype were transplanted into irradiated recipients along with 5 3 10 5 recipient bone marrow cells (2 independent experiments with a total of 8 recipients per genotype). Data represent mean 6 s.d. Two-tailed student's t-tests were used to assess statistical significance.
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were isolated as previously described 21, 22 . BrdU incorporation in vivo was measured by flow cytometry using the APC BrdU Flow Kit (BD Biosciences). To perform pyronin Y and DAPI staining, CD150 1 CD48 2 LSK HSCs were sorted into 100% ethanol and placed in the cold room overnight. The cells were then washed with PBS and stained with pyronin Y (1 mg ml 21 ) and DAPI (10 mg ml 21 ) for 30 min before flow cytometric analysis.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. Recipients in reconstitution assays were adult C57BL/Ka-CD45.1:Thy-1.2 mice, at least 8-weeks-old at the time of irradiation. pIpC (Amersham) was reconstituted in PBS and administered at 0.5 mg per g of body mass per day by intraperitoneal (i.p.) injection. The 5-bromodeoxyuridine (BrdU, Sigma) was administered as a single dose of 200 mg per kg of body mass by i.p. injection followed by 1 mg ml 21 BrdU in the drinking water. For long term BrdU administration, BrdU water was changed every 3 days. Doxycycline (Research Products International) was added to the water at a concentration of 0.2% (m/v) along with 1% sucrose (Fisher). Statistical methods. Multiple independent experiments were performed to verify the reproducibility of all experimental findings. Group data always represents mean 6 standard deviation. Unless otherwise indicated, two-tailed Student's t-tests were used to assess statistical significance. No randomization or blinding was used in any experiments. Experimental mice were not excluded in any experiments. In the case of measurements in which variation among experiments tends to be low (for example, HSC frequency) we generally examined between 3 to 6 mice. In the case of measurements in which variation among experiments tends to be higher (for example, reconstitution assays) we examined larger numbers of mice (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . PCR of genomic DNA for genotyping. To assess the degree of Nras G12D recombination in HSCs from Mx1-cre; Nras G12D/1 mice after pIpC treatment, bone marrow cells were harvested and stained for surface markers as described above. Single HSCs (CD150 1 CD48 2 LSK cells) were sorted into 96-well plates containing methylcellulose medium (M3434, Stem Cell Technologies) and incubated for 14 days at 37 uC. Cells from each colony were resuspended in PBS then incubated with alkaline lysis buffer (25 mM NaOH, 0.2 mM EDTA), boiled, then neutralized by addition of an equal volume of neutralizing buffer (40 mM Tris-HCl). The neutralized extract was used for PCR with the following primers: F2, 59-AGACGC GGAGACTTGGCGAGC-39; R1, 59-GCTGGATCGTCAAGGCGCTTTTCC-39. To genotype mouse tail DNA for the presence of the Nras G12D allele, primers R1 and F2 were used in addition to primer SD59, 59-AGCTAGCCACCATGGCTTG AGTAAGTCTGCA-39. To genotype for the presence of the Mx1-cre transgene, primers F1 and R1 were used: F1 59-ATTGCTGTCACTTGGTCGTGGC-39; R1, 59-GAAAATGCTTCTGTCCGTTTGC-39. To check the presence of the Rosa26-M2-rtTA transgene, the following primers were used: 59-AAAGTCGCTCTGAG TTGTTAT-39; 59-GCGAAGAGTTTGTCCTCAACC-39; and 59-GGAGCGGGA GAAATGGATATG-39. To genotype mice for the presence of the Col1A1-H2B-GFP transgene, the following primers were used: 59-CTGAAGTTCATCTGCAC CACC-39, 59-GAAGTTGTACTCCAGCTTGTGC-39. To genotype mice for the deletion of Stat5ab, the following primers were used: 59-GAAAGCAGCATGAAA GGGTTGGAG-39; 59-AGCAGCAACCAGAGGACTAC-39; and 59-AAGTTAT CTCGAGTTAGTCAGG-39. Flow cytometry and HSC isolation. Bone marrow cells were flushed from the long bones (tibias and femurs) with Hank's buffered salt solution without calcium or magnesium, supplemented with 2% heat-inactivated calf serum (HBSS; Invitrogen). Cells were triturated and filtered through a nylon screen (70 mm; Sefar America) to obtain a single-cell suspension. CD150 1 CD48 2 Lin 2 Sca1 1 c-kit 1 HSCs and CD150 2 CD48 2 Lin 2 Sca1 1 c-kit 1 MPPs were isolated as previously described 21, 22 . For isolation of HSCs, whole bone marrow cells were incubated with antibodies to lineage (Lin) markers including B220 (6B2), CD3 (KT31.1), CD5 (53-7.3), CD8 (53-6.7), Gr-1 (8C5), CD41 (MWReg30) and Ter119 (Ter-119) that were conjugated to FITC, anti-CD150 antibody (TC15-12F12.2) conjugated to PE, anti-CD48 antibody (HM48-1) conjugated to PE-Cy7, anti-c-kit antibody (2B8) conjugated to APC, and anti-Sca1 antibody (D7) conjugated to PerCP/Cy5.5 (all antibodies were purchased from BioLegend). After washing, cells were incubated with anti-APC conjugated to paramagnetic microbeads (Miltenyi Biotec). The microbead bound (c-kit 1 ) cells were then enriched using LS columns (Miltenyi Biotec). To identify CD45.2 1 HSCs, antibodies against CD45.2 (104-FITC; BioLegend) and CD45.1 (A20-APC780, BioLegend) were used. Non-viable cells were excluded from sorts and analyses using the viability dye 49,6-diamidino-2-phenylindole (DAPI) (1 mg ml 21 ). BrdU incorporation in vivo was measured by flow cytometry using the APC BrdU Flow Kit (BD Biosciences). To perform pyronin Y and DAPI staining, CD150 1 CD48 2 LSK HSCs were sorted into 100% ethanol and placed at 4uC overnight. The cells were then washed with PBS and stained with pyronin Y (1 mg ml 21 ) and DAPI (10 mg ml 21 ) for 30 min before flow cytometric analysis.
Long-term competitive repopulation assay. Adult recipient mice (CD45.1) were irradiated with an Orthovoltage X-ray source delivering approximately 300 rad min 21 in two equal doses of 540 rad, delivered at least 2 h apart. Cells were injected into the retro-orbital venous sinus of anaesthetized recipients. Beginning 4 weeks after transplantation and continuing for at least 16 weeks, blood was obtained from the tail veins of recipient mice, subjected to ammonium-chloride potassium red cell lysis, and stained with directly conjugated antibodies to CD45.2 (104), CD45.1 (A20), B220 (6B2), Mac-1 (M1/70), CD3 (KT31.1) and Gr-1 (8C5) to monitor engraftment. BrdU incorporation by myeloid progenitors. Two and a half hours after BrdU administration, whole bone marrow cells were incubated first with anti-c-kit antibody conjugated to biotin (2B8) then with antibodies to lineage (Lin) markers including B220 (6B2), CD3 (KT31.1), CD5 (53-7.3), CD8 (53-6.7), Gr-1 (8C5), CD41 (MWReg30) and Ter119 (Ter-119) that were conjugated to phycoerythrin (PE), anti-CD34 antibody (eBioscience, RAM34) conjugated to FITC, anti-CD16/ CD32 antibody (93) conjugated to PE-Cy7, streptavidin conjugated to Alexa700 (Invitrogen S21383), and anti-Sca1 antibody (D7) conjugated to PerCP/Cy5.5 (all antibodies were purchased from BioLegend unless otherwise stated). BrdU incorporation was measured by flow cytometry using the APC BrdU Flow Kit (BD Biosciences). Western blotting. The same number of cells (30,000 cells for CD48 2 LSK cells or CD48 1 LSK cells; 100,000 cells for LSK or Lineage 2 c kit 1 Sca-1 2 cells) from each population to be analysed were sorted into HBSS with 2% FCS. The cells were then washed and incubated with 100 ng ml 21 thrombopoietin and 100 ng ml 21 stem cell factor at 37 uC for 30 min. The cells then were washed with PBS and precipitated with trichloroacetic acid (TCA) at a final concentration of 10% TCA. Extracts were incubated on ice for 15 min and spun down for 10 min at 16,100g at 4 uC. The supernatant was removed and the pellets were washed with acetone twice and then dried. The protein pellets were solubilized with solubilization buffer (9 M urea, 2% Triton X-100, 1% DTT) before adding lithium dodecyl sulphate loading buffer (Invitrogen). Proteins were separated on a Bis-Tris polyacrylamide gel (Invitrogen) and transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore). All antibodies were purchased from Cell Signaling Technology. These include anti-pERK (T202/Y204), anti-pAkt (T308), anti-pS6 (S240/244), anti-pStat5 (Y694), anti-Stat3 (Y705), anti-ERK (137F5), anti-Stat5 (3H7), anti-pp38 (T180/Y182) and anti-b-actin (8H10D10). Gene expression profiling. CD150 1 CD48 2 LSK HSCs and CD150 2 CD48 2 LSK MPPs were isolated by flow cytometry. Total RNA was isolated using Trizol (Invitrogen) followed by Qiagen RNeasy microkit purification according to the manufacturer's protocols. For microarray analysis, reverse transcription and linear amplification was performed on total RNA using the NuGen Ovation pico WTA system version 2 and then purified with the Qiaquick PCR purification kit (Qiagen). Six micrograms of amplified cDNAs were labelled with biotin using the Encore Biotin Module (NuGen) and submitted to the Microarray Core Facility of the University of Michigan Comprehensive Cancer Center for hybridization to Affymetrix Mouse Genome 430 2.0 Arrays. Statistical analyses were performed using R (ref. 31) version 2.15.2 and Bioconductor version 2.11 (ref. 32). Gene expression signals were normalized to the trimmed average of 500 using the Affymetrix MAS 5.0 algorithm. MAS5 signals less than 2 were set to 2 before log 2 transformation. Probe sets with MAS5 absent calls for all samples were excluded. Differential expression analysis was performed by limma 33 with estimation of fold change. Probe sets with limma P-value ,0.05 and fold change .2 were considered differentially expressed. Gene Set Enrichment Analysis 34 was used to assess pathway enrichment. Gene expression data have been deposited to the Gene Expression Omnibus with accession number GSE45194 (http://www.ncbi.nlm.nih.gov/geo/). Quantitative RT-PCR. Total RNA was collected as described above and reverse transcription was performed with the High Capacity cDNA reverse transcription kit (Applied Biosystems). Real time PCR was performed with Absolute SYBR Green Rox mix (Thermo Scientific) using an ABI 7300 PCR machine. RNA from 100 cells was used for each reaction. Transcript levels were normalized to b-actin. Extended Data Figure 4 | Nras G12D (G12D/1) expression increased the reconstituting potential of CD150 2 CD48 2 LSK MPPs but did not affect the reconstituting potential of CD150 1 CD48 1 LSK, or CD150 2 CD48 1 LSK progenitors in irradiated mice. a-c, Ten donor MPPs (a), 25 CD150 1 CD48 1 LSK progenitors (b), or 100 CD150 -CD48 1 LSK progenitors (c) from Mx1-cre; Nras G12D/1 (G12D/1) or littermate control mice at 2 weeks after pIpC treatment were transplanted into irradiated recipient mice along with 3 3 10 5 recipient bone marrow cells. Data represent mean 6 s.d. for donor blood cells in the myeloid (Gr-1 1 or Mac-1 1 cells), B (B220 1 ) and T (CD3 1 ) cell lineages. Two-tailed Student's t-tests were used to assess statistical significance. None of the time points were significantly different between treatments. The data represent two independent experiments with 4 recipient mice per donor. not associated with the development of leukaemia. a-d, White blood counts (WBC), hemoglobulin (Hb) levels, platelet counts and spleen masses for recipient mice from primary transplants (a, from Fig. 1d ), secondary transplants (b, from Fig. 2a ), tertiary transplants (c, from Fig. 2b ) and quaternary transplants (d, from Fig. 2c ). In all cases, these blood cell counts were collected from mice after the analysis of blood cell reconstitution was complete (at least 20 weeks after transplantation). The transplanted mice were observed for a median time of 260 (162-315) days for primary recipient mice, 194 (122-264) days for secondary recipient mice, 224 (176-336) days for tertiary recipient mice, and 280 (279-280) days for quaternary recipient mice. We never observed evidence of leukaemia or MPN by histology in these mice. Across all of the experiments, only two recipients of Nras G12D/1 cells and two recipients of control cells died spontaneously. Data represent mean 6 s.d. Two-tailed Student's t-tests were used to assess statistical significance and none of the comparisons showed significant difference. but increased the rate at which MPPs divide. a, Flow cytometric analysis of GFP expression in whole bone marrow cells from Nras G12D/1 or littermate control mice after 12 weeks of chase without doxycycline. b, Median GFP fluorescence intensity of H2B-GFP 2 , H2B-GFP lo and H2B-GFP hi HSCs from wild type and Nras G12D/1 mice (n 5 8 mice per genotype). GFP levels in control HSCs were set to one for comparison to relative levels in Nras G12D/1 HSCs. c, Nras G12D increased the rate of division by MPPs. Flow cytometric analysis of GFP expression in CD150 2 CD48 2 LSK MPPs from Mx1-cre; Nras G12D/1 ; Col1A1-H2B-GFP; Rosa26-M2-rtTA mice (G12D/1) and littermate controls (con) after 12 weeks of chase (n 5 8 mice per genotype). Relative to control MPPs, Nras G12D/1 MPPs included significantly more H2B-GFP 2 frequently cycling cells and significantly fewer H2B-GFP lo MPPs (P , 0.05 by two-way ANOVA and post hoc pairwise t-tests). d, We continuously administered BrdU to Mx1-cre; Nras G12D/1 versus control mice for 1 to 30 days and determined the frequency of BrdU 1 HSCs (1 day BrdU data are from Fig. 1a ). Data represent mean 6 s.d. Two-tailed Student's t-tests were used to assess statistical significance unless stated otherwise. *P , 0.05, **P , 0.01, ***P , 0.001. 
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